Switch theme
Sign up to access all valuation multiples
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
2021
170
LTM Revenue $7.3M
LTM EBITDA -$294M
$184M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alumis has a last 12-month revenue (LTM) of $7.3M and a last 12-month EBITDA of -$294M.
In the most recent fiscal year, Alumis achieved revenue of n/a and an EBITDA of -$298M.
Alumis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alumis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $7.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$294M | XXX | -$298M | XXX | XXX | XXX |
| EBITDA Margin | -3997% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$314M | XXX | -$301M | XXX | XXX | XXX |
| EBIT Margin | -4268% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$307M | XXX | -$294M | XXX | XXX | XXX |
| Net Margin | -4178% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alumis's stock price is $3.
Alumis has current market cap of $361M, and EV of $184M.
See Alumis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $184M | $361M | XXX | XXX | XXX | XXX | $-7.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alumis has market cap of $361M and EV of $184M.
Alumis's trades at n/a EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate Alumis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alumis has a P/E ratio of -1.2x.
See valuation multiples for Alumis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $361M | XXX | $361M | XXX | XXX | XXX |
| EV (current) | $184M | XXX | $184M | XXX | XXX | XXX |
| EV/Revenue | 25.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 25.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlumis's last 12 month revenue growth is 68%
Alumis's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Alumis's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alumis's rule of X is -3826% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alumis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 68% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -3997% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3826% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alumis acquired XXX companies to date.
Last acquisition by Alumis was XXXXXXXX, XXXXX XXXXX XXXXXX . Alumis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alumis founded? | Alumis was founded in 2021. |
| Where is Alumis headquartered? | Alumis is headquartered in United States of America. |
| How many employees does Alumis have? | As of today, Alumis has 170 employees. |
| Who is the CEO of Alumis? | Alumis's CEO is Mr. Martin Babler. |
| Is Alumis publicy listed? | Yes, Alumis is a public company listed on NAS. |
| What is the stock symbol of Alumis? | Alumis trades under ALMS ticker. |
| When did Alumis go public? | Alumis went public in 2024. |
| Who are competitors of Alumis? | Similar companies to Alumis include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alumis? | Alumis's current market cap is $361M |
| What is the current revenue of Alumis? | Alumis's last 12 months revenue is $7.3M. |
| What is the current revenue growth of Alumis? | Alumis revenue growth (NTM/LTM) is 68%. |
| What is the current EV/Revenue multiple of Alumis? | Current revenue multiple of Alumis is 25.0x. |
| Is Alumis profitable? | Yes, Alumis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alumis? | Alumis's last 12 months EBITDA is -$294M. |
| What is Alumis's EBITDA margin? | Alumis's last 12 months EBITDA margin is -3997%. |
| What is the current EV/EBITDA multiple of Alumis? | Current EBITDA multiple of Alumis is -0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
